Levothyroxine Brillpharma 25 microgram/5 ml Oral Solution

Endocrinology

Therapeutic indications include:

  1. Hypothyroidism (congenital or acquired)
  2. Diffuse non-toxic goitre
  3. Goitre associated with Hashimoto’s thyroiditis
  4. Suppression therapy in thyroid carcinoma1
Strength 25 microgram/5 ml
Pack Size 100 ml
Measuring Device 5 ml oral syringe (graduated at every 0.1 ml) and an adaptor for the syringe.
Regulatory Status POM
Flavour
Suitable for Vegetarians Yes
GTIN 5060712420089
PIP code 125-0091

1 Summary of Product Characteristics (SPCs) and Patient Information Leaflets (PILs) can be found on the EMC website: https://www.medicines.org.uk/emc/product/13843/smpc

Manufacturing

Our quality and safety teams monitor and analyse each stage of the production and distribution process to make sure our products are of the highest quality. The application of Good Manufacturing Practice (GMP) means that we have the appropriate standards and procedures in place to help us achieve this.

How to report adverse events

Adverse events should be reported.

If you are based in the UK, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk.

Adverse events should also be reported to Brill Pharma
Tel: 0044 (0) 1582 545505 Email: info@brillpharma.co.uk

If you are based outside of the UK, please report adverse events to Brill Pharma using the contact details provided above.

Have a question?

If you have a question about Brill Pharma or any products in our range please get in touch

Tel: 0044 (0) 1582 545505 Email: info@brillpharma.co.uk

Job Number: BLL-007-007Date of Preparation: March 2023